PRETREATMENT WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK-CANCER

  • 1 January 1985
    • journal article
    • research article
    • Vol. 14  (6) , 391-393
Abstract
Average survival for advanced head and neck cancer (AHNC) is 18 months. In an attempt to improve this we treated 29 AHNC patients between 1978-82 with two courses of chemotherapy. Chemotherapy consisted of cyclophosphamide, methotrexate, 5 fluorouracil and bleomycin; or bleomycin, cisplatinum and methotrexate. Chemotherapy was given prior to definitive therapy of radiotherapy or radiotherapy and surgery. All patients were stage 3 or 4. All patients were Eastern Co-operative Oncology Group status performance 0 or 1. Response to chemotherapy did not improve survival. Pretreatment with chemotherapy, should be investigational until increased survival has been documented.

This publication has 0 references indexed in Scilit: